In this episode of Midwest Momentum Eddie Pauline, CEO of Ohio Life Sciences, shares that Ohio has seen a 45% surge in industry engagement. Discover how this growth is being fueled by strategic advocacy. Plus, he spotlights crucial intellectual property rights issues amid shifting federal policies. This could cause a ripple effect on drug pricing, innovation, and commercialization.

Explore the transformative potential of personalized healthcare through groundbreaking biomarker testing and pharmacogenomics, promising safer, tailored medical treatments. Eddie also shares insights into how state-backed funding programs like SBIR and STTR are vital for nurturing entrepreneurial talent and innovation. As Ohio carves out its competitive edge in the life sciences arena, we emphasize the urgent need for workforce development, particularly in pharmaceutical manufacturing, with initiatives like the BioPathways program paving the way for future talent. Join us to uncover how these efforts are setting the stage for economic growth and a robust, skilled workforce in Ohio's life sciences sector.

- Overview of Ohio Life Sciences and its mission
- Membership growth and the importance of community awareness
- Legislative issues affecting intellectual property rights in biotech
- Importance of biomarker testing for personalized healthcare
- Advocacy for SBIR/STTR funding and state support
- Workforce challenges in the pharmaceutical manufacturing sector
- BioPathways program for K-12 education in life sciences
- Investment landscape and the goal of keeping innovations in Ohio